Guangxia Deng

Title: Innovations of Guangxia Deng in Cancer Treatment

Introduction

Guangxia Deng is a notable inventor based in Jinan, China. He has made significant contributions to the field of medicine, particularly in the treatment of non-small cell lung carcinoma. His innovative approach has led to the development of a unique strain that shows promise in cancer therapy.

Latest Patents

Guangxia Deng holds a patent for the "Application of Derivative of Clostridium Ghonii." This patent focuses on the application of derivatives, specifically the MW-DCG-HNCv-18 strain, in the preparation of medicines for treating non-small cell lung carcinoma. The invention reveals that the MW-DCG-HNCv-18 strain exhibits a specific inhibition effect on non-small cell lung carcinoma for the first time. The inhibition effect is significantly superior to that of other known similar strains. Furthermore, it has been discovered that the MW-DCG-HNCv-18 strain has a more prominent inhibition effect when combined with Docetaxel injection.

Career Highlights

Throughout his career, Guangxia Deng has worked with various companies, including Shandong Xinchuang Biotechnology Co., Ltd. and Shandong Xinchuang Biological Technology Co., Ltd. His work in these organizations has contributed to advancements in biotechnology and cancer treatment.

Collaborations

Guangxia Deng has collaborated with notable colleagues such as Laitian Xing and Yong Wang. Their combined expertise has furthered research and development in the field of cancer therapies.

Conclusion

Guangxia Deng's innovative work in the application of derivatives for cancer treatment highlights his significant contributions to medical science. His patent demonstrates the potential for new therapies in combating non-small cell lung carcinoma.